<DOC>
	<DOC>NCT00404573</DOC>
	<brief_summary>This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo</brief_summary>
	<brief_title>Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Male and female inpatients, 1865 years of age, meeting DSMIVTR criteria for schizophrenia and having a Total Positive and Negative Syndrome Scale (PANSS) Score &gt;=80 and &lt;=120. A score &gt;=4 on item P1 (delusions) or P3 (hallucinatory behavior) and a score of &gt;=4 on item P2 (conceptual disorganization) or P6 (suspiciousness/persecution) of the PNASS Patients with documented disease of the central nervous system that can interfere with the trial assessments, including but not limited to stroke, tumor, Parkinson's, organic brain disease, seizure disorder (except for febrile convulsions during infancy), chronic infection, or neurosyphilis; or patients who have suffered a traumatic brain injury resulting in significant impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>